Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Shares of Shire Plc spiked overnight after increased rumors that Japanese pharma giant Takeda could be closer to making a deal to acquire the rare disease company.
A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences, a drug discovery engine co-founded with Versant Ventures in 2011.
Pfizer Inc. may have a new potential buyer for its consumer health business unit. Mega-consumer goods company Procter & Gamble is reportedly interested in acquiring the business.
Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
Another major healthcare buyout may be on the horizon. According to reports, Walmart may be in talks to buy health insurer Humana.
In an initial public offering, Unum Therapeutics snagged nearly $70 million to fund its antibody-coupled T-cell receptor technology.
Yesterday’s news that Takeda Pharmaceuticals was considering acquiring Shire is raising the possibility of a bidding war. But it’s also having decidedly different effects on the two companies’ stock prices.
Following an agreement to sell its share of a consumer health business unit to GlaxoSmithKline for $13 billion new Novartis Chief Executive Officer Vasant Narasimhan has some excess cash to use to shape the company in the coming years.